desipramine has been researched along with atenolol in 45 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.44) | 18.7374 |
| 1990's | 1 (2.22) | 18.2507 |
| 2000's | 14 (31.11) | 29.6817 |
| 2010's | 26 (57.78) | 24.3611 |
| 2020's | 2 (4.44) | 2.80 |
| Authors | Studies |
|---|---|
| Danelian, E; Hämäläinen, MD; Hansson, A; Karlén, A; Karlsson, R; Lennernäs, H; Löfâs, S; Winiwarter, S | 1 |
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Faller, B; Wohnsland, F | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Caron, G; Ermondi, G | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Alimuddin, M; Bulloch, D; Dahl, R; Grant, D; Lee, N; Peacock, M | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Andrisano, V; Barril, X; Bartolini, M; Carreiras, Mdo C; de los Ríos, C; García, AG; Huertas, O; León, R; López, B; López, MG; Luque, FJ; Marco-Contelles, J; Rodríguez-Franco, MI; Samadi, A; Villarroya, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Avdeef, A; Tam, KY | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Brea, J; Cadavid, MI; Campillo, NE; Ceballos, P; Gil, C; Loza, MI; Martínez, A; Moro, MA; Pérez, C; Pérez, DI; Perez-Castillo, A; Redondo, M; Val, C; Zarruk, JG | 1 |
| Andrisano, V; Bolognesi, ML; Carloni, P; Cavalli, A; Chiriano, G; De Simone, A; Legname, G; Mancini, F; Martinez, A; Perez, DI; Roberti, M | 1 |
| Alonso-Gil, S; Campillo, NE; Castro, A; Encinas, A; Gil, C; Martinez, A; Morales-Garcia, JA; Palomo, V; Perez, C; Perez, DI; Perez-Castillo, A; Soteras, I | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Alonso-Gil, S; Chavarría, C; Gil, C; Morales Garcia, JA; Pérez, C; Perez, DI; Pérez-Castillo, A; Porcal, W; Souza, JM | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, J; Chen, X; Huang, L; Li, X; Sun, Y | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Bello, ML; Gil, C; Kraemer, BC; Lecourtois, M; Liachko, NF; Martinez, A; Miguel, L; Perez, C; Perez, DI; Redondo, M; Salado, IG | 1 |
| Huang, L; Li, X; Meng, F; Miao, H; Sun, Y | 1 |
| Cahlíková, L; Chlebek, J; Hošt'álková, A; Opletal, L; Pérez, DI; Šafratová, M; Štěpánková, Š | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Guo, QL; Huang, SL; Huang, ZS; Li, D; Liu, ZQ; Ou, TM; Tan, JH; Wang, HG; Wang, N; Wu, JQ; Xia, CL | 1 |
| Campillo, NE; Geiger, L; Gil, C; González, S; Li, L; Martinez, A; Morales, AV; Perez, DI; Salado, IG; Sebastián-Pérez, V; Zaldivar-Diez, J | 1 |
| Gu, Y; Ma, T; Pusch, S; von Deimling, A; Xu, Y; Yang, L; Zha, X; Zhu, Q; Zou, F | 1 |
| Gu, Y; Hua, J; Ma, T; Pusch, S; von Deimling, A; Xu, Y; Yang, L; Zha, X; Zhu, Q; Zou, F | 1 |
| Campillo, NE; Cañada, FJ; Canales, A; Carvalho, I; Chierrito, TPC; Martinez, A; Martínez-Gonzalez, L; Pedersoli-Mantoani, S; Perez, C; Pérez, DI; Roca, C; Sebastian-Pérez, V | 1 |
| Dolezal, R; Hepnarova, V; Hrabinova, M; Jost, P; Jun, D; Kaping, D; Kerhartova, M; Korabecny, J; Kuca, K; Kucera, T; Matouskova, L; Mezeiova, E; Muckova, L; Nepovimova, E; Pham, NL; Soukup, O; Spilovska, K; Staud, F; Vykoukalova, N | 1 |
| An, B; Hu, J; Huang, L; Li, X; Li, Z; Pan, T | 1 |
| Acevedo, O; Dasararaju, G; Devadasan, V; Halakova, D; Jayaprakash, V; Kovacikova, L; Mohd Siddique, MU; Mondal, SK; Prnova, MS; Shilkar, D; Stefek, M; Thakur, A; Yasmin, S | 1 |
| Chaikuad, A; de Lago, E; Gil, C; Gomez-Almeria, M; Gonzalo-Consuegra, C; Knapp, S; Lietha, D; Martín-Requero, A; Martinez, A; Martínez-González, L; Monti, B; Nozal, V; Palomo, V; Pérez-Cuevas, E; Petralla, S; Ramírez, D; Santana, P | 1 |
| Kanazawa, Y; Kitada, Y; Miyauchi, T; Nakamichi, H; Satoh, S | 1 |
| Kitada, Y; Kosasa, T; Miyauchi, T; Satoh, S | 1 |
| Cox, HS; Dart, AM; Du, XJ; Esler, MD | 1 |
| Horinouchi, T; Koike, K; Michikawa, H; Tanaka, Y; Yamashita, Y | 1 |
1 review(s) available for desipramine and atenolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
44 other study(ies) available for desipramine and atenolol
| Article | Year |
|---|---|
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
Topics: Humans; Intestinal Absorption; Liposomes; Pharmaceutical Preparations; Pharmacokinetics; Predictive Value of Tests; Surface Plasmon Resonance | 2000 |
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
Topics: Alkanes; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Membranes, Artificial; Octanols; Permeability; Pharmaceutical Preparations; Solubility; Water | 2001 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Determination of log D via automated microfluidic liquid-liquid extraction.
Topics: Automation; Biopharmaceutics; Microfluidic Analytical Techniques; Pharmacokinetics | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholinesterase; Calcium; Calcium Channel Blockers; Catalytic Domain; Cell Death; Cell Line, Tumor; Cholinesterase Inhibitors; Cytosol; Dihydropyridines; Humans; Hydrogen Peroxide; Kinetics; Ligands; Models, Molecular; Peptide Fragments; Permeability; Tacrine | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
Topics: Animals; Blood-Brain Barrier; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease Models, Animal; Enzyme Inhibitors; Infarction, Middle Cerebral Artery; Male; Mice; Neuroprotective Agents; Permeability; Quinazolines; Stroke | 2012 |
A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cell Survival; Chickens; Humans; Imidazoles; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Models, Molecular; Neurons; Small Molecule Libraries; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Structure-Activity Relationship | 2012 |
5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Astrocytes; Blood-Brain Barrier; Cell Death; Cell Differentiation; Cell Membrane Permeability; Cells, Cultured; Glycogen Synthase Kinase 3; Hippocampus; Humans; Imines; In Vitro Techniques; Lipopolysaccharides; Membranes, Artificial; Microglia; Models, Molecular; Neural Stem Cells; Neurogenesis; Neurons; Neuroprotective Agents; Nitrites; Protein Binding; Rats; Structure-Activity Relationship; Substrate Specificity; Swine; Thiadiazoles | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Microwave-assisted synthesis of hydroxyphenyl nitrones with protective action against oxidative stress.
Topics: Anti-Inflammatory Agents; Antioxidants; Blood-Brain Barrier; Cell Survival; Dose-Response Relationship, Drug; Humans; Microwaves; Molecular Structure; Neuroblastoma; Neuroprotective Agents; Nitrogen Oxides; Oxidative Stress; Oxidopamine; Peroxynitrous Acid; Structure-Activity Relationship; Tyrosine | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Electrophorus; Humans; Isoflavones; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Swine; Tacrine | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Benzothiazoles; Blood-Brain Barrier; Casein Kinase I; Cell Membrane Permeability; Cells, Cultured; DNA-Binding Proteins; Drosophila; Drug Design; Drug Discovery; HEK293 Cells; Heterocyclic Compounds; High-Throughput Screening Assays; Humans; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Neurons; Neurotoxicity Syndromes; Phosphorylation; Protein Kinase Inhibitors; Substrate Specificity | 2014 |
Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Humans; Indans; Inhibitory Concentration 50; Ligands; Peptide Fragments; Permeability; Protein Aggregates | 2014 |
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
Topics: Acetylcholinesterase; Alzheimer Disease; Amaryllidaceae Alkaloids; Biological Transport; Blood-Brain Barrier; Cholinesterase Inhibitors; Humans; In Vitro Techniques; Molecular Structure | 2015 |
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line; Cholinesterase Inhibitors; Drug Design; Glutathione; Humans; Quinolines; Reactive Oxygen Species | 2017 |
Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
Topics: Animals; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Indoles; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Neural Stem Cells; Neuroprotective Agents; Protein Kinase Inhibitors; Structure-Activity Relationship | 2017 |
Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.
Topics: Cell Survival; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; HEK293 Cells; Humans; Isocitrate Dehydrogenase; Molecular Docking Simulation; Molecular Structure; Mutation; Oxazolidinones; Pyrazines; Structure-Activity Relationship | 2017 |
Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening.
Topics: Allosteric Site; Blood-Brain Barrier; Brain Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glioma; HEK293 Cells; Humans; Isocitrate Dehydrogenase; Molecular Docking Simulation; Molecular Structure; Mutation; Small Molecule Libraries; Structure-Activity Relationship | 2018 |
Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Indoles; Molecular Structure; Piperidines; Structure-Activity Relationship | 2018 |
The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line; Cholinesterase Inhibitors; Cricetulus; Dose-Response Relationship, Drug; Humans; Molecular Structure; Quinolines; Structure-Activity Relationship; Tacrine | 2018 |
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Clioquinol; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Design; Humans; Ligands; Mice; Rats; Rolipram | 2019 |
Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
Topics: Aldehyde Reductase; Animals; Caco-2 Cells; Catalytic Domain; Dogs; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Madin Darby Canine Kidney Cells; Male; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Protein Binding; Rats, Wistar; Structure-Activity Relationship; Thiazolidinediones | 2021 |
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.
Topics: Amyotrophic Lateral Sclerosis; Animals; Brain; Case-Control Studies; DNA-Binding Proteins; Humans; Inflammation; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Transgenic; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; Spinal Cord; Tissue Distribution | 2022 |
Involvement of alpha- and beta 1-adrenergic mechanisms in the immobility-reducing action of desipramine in the forced swimming test.
Topics: Animals; Atenolol; Brain; Desipramine; Drug Interactions; Helplessness, Learned; Humans; Isoproterenol; Male; Motor Activity; Phenoxybenzamine; Phenylephrine; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Swimming | 1983 |
Further studies on the suppressing effect of isoproterenol on the immobility-reducing action of desipramine in the forced swimming test.
Topics: Animals; Atenolol; Clonidine; Desipramine; Isoproterenol; Male; Motor Activity; Phenylephrine; Rats; Rats, Inbred Strains; Swimming; Yohimbine | 1983 |
Sympathetic activation triggers ventricular arrhythmias in rat heart with chronic infarction and failure.
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Atenolol; Cardiac Pacing, Artificial; Desipramine; Electric Stimulation; Electrocardiography; Female; Heart Failure; Lung; Male; Myocardial Infarction; Myocardium; Norepinephrine; Perfusion; Potassium; Propanolamines; Rats; Rats, Sprague-Dawley; Sex; Statistics, Nonparametric; Sympathetic Nervous System; Tachycardia, Ventricular | 1999 |
Pharmacological characterization of the beta-adrenoceptor that mediates the relaxant response to noradrenaline in guinea-pig tracheal smooth muscle.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Albuterol; Animals; Atenolol; Bupranolol; Butoxamine; Desipramine; Desoxycorticosterone; Dose-Response Relationship, Drug; Female; Guinea Pigs; Histamine; Imidazoles; In Vitro Techniques; Male; Muscle Relaxation; Muscle, Smooth; Norepinephrine; Phentolamine; Propanolamines; Propranolol; Receptors, Adrenergic, beta-1; Trachea | 2007 |